非标准病毒基因组衍生RNA激活TLR3和I型IFN信号诱导小鼠疫苗接种中cDC1依赖的CD8+ T细胞应答
本研究在小鼠中探究DDOs佐剂诱导1型免疫的早期先天机制。DDO皮下注射后,cDC1以TLR3和I型IFN依赖方式在引流淋巴结积聚,该积聚为抗原特异性CD8+ T细胞应答所必需。与poly I:C不同,DDO仅在注射部位而非引流淋巴结诱导I型IFN,并诱导不同的炎性细胞因子谱。
要点
- DDOs通过TLR3和I型IFN依赖途径诱导cDC1在引流淋巴结快速积聚。
- 淋巴结中cDC1积聚是DDOs诱导抗原特异性CD8+ T细胞应答所必需。
- DDOs在注射部位而非引流淋巴结诱导I型IFN,且炎性细胞因子谱与poly I:C不同。
核心结论
- DDOs代表一种强大的新型佐剂,可用于抗胞内病原体疫苗接种。
研究设计与样本
- 小鼠体内研究,探究DDOs皮下注射后早期先天免疫应答及对CD8+ T细胞应答的影响。
主要发现
- DDO皮下注射后,cDC1以TLR3和I型IFN依赖方式在引流淋巴结迅速积聚。
- 引流淋巴结中cDC1积聚为抗原特异性CD8+ T细胞应答所必需。
- 与poly I:C相比,DDO给药在注射部位而非引流淋巴结诱导I型IFN表达。
- DDOs诱导的炎性细胞因子谱与poly I:C诱导的不同。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a critical need to develop vaccine adjuvants that induce robust immune responses able to protect against intracellular pathogens, including viruses. Previously, we described defective viral genome-derived oligonucleotides (DDOs) as novel adjuvants that strongly induce type 1 immune responses, including protective Th1 CD4+ T-cells and effector CD8+ T-cells in mice. Here, we unravel the early innate response required for this type 1 immunity induction. Upon DDO subcutaneous injection, type 1 conventional dendritic cells (cDC1s) accumulate rapidly in the draining lymph node in a Toll-like receptor 3 (TLR3)- and type I interferon (IFN)-dependent manner. cDC1 accumulation in the lymph node is required for antigen-specific CD8+ T-cell responses. Notably, in contrast to poly I:C, DDO administration resulted in type I IFN expression at the injection site, but not in the draining lymph node. Additionally, DDOs induced an inflammatory cytokine profile distinct from that induced by poly I:C. Therefore, DDOs represent a powerful new adjuvant to be used during vaccination against intracellular pathogens.
引用
- Fisher DG, Gnazzo V, Holthausen DJ, et al. Non-standard viral genome-derived RNA activates TLR3 and type I IFN signaling to induce cDC1-dependent CD8+ T-cell responses during vaccination in mice. Vaccine. 2022. PMID: 36333225. doi:10.1016/j.vaccine.2022.10.052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。